title: Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?
abstract: Recent advances in the treatment of early breast cancer have improved clinical outcomes and prolonged survival, especially in women with endocrine-responsive disease. However, cancer therapies including cytotoxic chemotherapy, ovarian suppression, and aromatase inhibitors can drastically reduce circulating estrogen, increasing bone loss and fracture risk. Because most women with early breast cancer will live for many years, it is important to protect bone health during cancer therapy. Several recent clinical trials combining adjuvant endocrine therapy with bisphosphonates have demonstrated efficacy for preventing cancer treatment-induced bone loss in pre- and postmenopausal women with early breast cancer. The largest body of evidence supporting the use of adjuvant bisphosphonates comes from studies with zoledronic acid; however, studies with risedronate, ibandronate, and denosumab (a biologic agent) have also demonstrated efficacy for preventing bone loss. Adding zoledronic acid to endocrine therapy prevents bone loss and improves bone mineral density (BMD). In addition, preclinical studies suggest that bisphosphonates have direct and indirect antitumor activity, such as inducing tumor cell apoptosis, reducing tumor cell adhesion and invasion, reducing angiogenesis, activating immune responses, and synergy with chemotherapy agents, among others. Clinical trials have demonstrated significantly improved disease-free survival in patients receiving adjuvant endocrine therapy plus zoledronic acid compared with endocrine therapy alone. Ongoing studies will further define the role of adjuvant bisphosphonates in maintaining bone health and improving clinical outcomes. The available evidence suggests that pre- and postmenopausal patients may receive clinical benefit from including bisphosphonates as part of their adjuvant treatment regimen for endocrine-responsive early breast cancer.
authors.affiliation: Department of Surgery, Medical University of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria.
authors.forename: Michael
authors.initials: M
authors.lastname: Gnant
authors.forename: Peter
authors.initials: P
authors.lastname: Blaha
authors.forename: Peter
authors.initials: P
authors.lastname: Dubsky
authors.forename: Ruth
authors.initials: R
authors.lastname: Exner
authors.forename: Florian
authors.initials: F
authors.lastname: Fitzal
authors.forename: Emanuel
authors.initials: E
authors.lastname: Sporn
authors.forename: Peter
authors.initials: P
authors.lastname: Panhofer
authors.forename: Andrea Dal
authors.initials: AD
authors.lastname: Borgo
authors.forename: Sinda
authors.initials: S
authors.lastname: Bigenzahn
authors.forename: Guenther
authors.initials: G
authors.lastname: Steger
authors.forename: Raimund
authors.initials: R
authors.lastname: Jakesz